GenVec, Inc. (NASDAQ:GNVC) Files An 8-K Submission of Matters to a Vote of Security Holders


GenVec, Inc. (NASDAQ:GNVC) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 15, 2017, GenVec, Inc. (GenVec) held a special meeting of
shareholders (the Special Meeting). GenVec filed a Definitive
Proxy Statement for the proposals voted upon at the Special
Meeting with the SEC on May 12, 2017, including the proposal to
adopt the Agreement and Plan of Merger, dated as of January 24,
2017, among GenVec, Intrexon GV Holding, Inc. (Merger Sub) and
Intrexon Corporation (the Merger Agreement). to the terms of the
Merger Agreement, Merger Sub will merge with and into GenVec (the
Merger). As described below, the Merger Agreement was adopted,
and GenVec anticipates completion of the Merger and the other
transactions contemplated by the Merger Agreement on or about
June 16, 2017.

As of April28, 2017, the record date for the Special Meeting,
2,273,632shares of common stock of GenVec (GenVec Common Stock)
were issued and outstanding and entitled to vote at the Special
Meeting. A quorum of1,276,211 shares of GenVec Common Stock, or
approximately 56.13% of the total shares entitled to vote, were
represented in person or by proxy at the Special Meeting. The
number of votes cast for, against or withheld, as well as
abstentions and broker non-votes, if applicable, with respect to
each proposal is set out below:

Proposal No.1Adoption of the Merger Agreement. The
Merger Agreement was adopted.

For Against Abstain Broker Non-Votes
1,218,493 50,676 7,042

Proposal No.2Approval on a non-binding basis of compensation
payable to GenVecs executive officers
. The compensation
payable was approved.

For Against Abstain Broker Non-Votes
976,460 124,317 175,434

No other proposals were submitted at the Special Meeting.

About GenVec, Inc. (NASDAQ:GNVC)

GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company’s lead product candidate is CGF166. The Company’s vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.

An ad to help with our costs